# v4.20

## Related releases

## Data changes

### Alteration

```
BIRC3 Background Updated
BRCA1 I379M Added
BTG1 Q36H Added
CDKN2A P72L
CDKN2A G65R Added
CDKN2A G65S Added
CDKN2A D68H Added
CEBPA P282_S334ins [bZIP Domain In-Frame Insertions] Added
CEBPA P282_S334del [bZIP Domain In-Frame Deletions] Added
CEBPA P282_S334trunc [bZIP Domain Truncating Mutations] Added
CEBPA Background Updated
CEBPA A278_T345ins [bZIP Region In-Frame Insertions] Name Changed
	 New: A278_T345ins [bZIP Region In-Frame Insertions]
	 Old: P282_S334ins [bZIP Domain In-Frame Insertions]
CEBPA A278_T345del [bZIP Region In-Frame Deletions] Name Changed
	 New: A278_T345del [bZIP Region In-Frame Deletions]
	 Old: P282_S334del [bZIP Domain In-Frame Deletions]
CEBPA A278_T345trunc [bZIP Domain Truncating Mutations] Name Changed
	 New: A278_T345trunc [bZIP Domain Truncating Mutations]
	 Old: P282_S334trunc [bZIP Domain Truncating Mutations]
CEBPA M1_V119trunc Added
CEBPA K313dup Added
CEBPA R297G Added
CEBPA K298T Added
CEBPA R300G Added
CEBPA K302N Added
CEBPA P272_R358ins [bZIP Region In-Frame Insertions] Name Changed
	 New: P272_R358ins [bZIP Region In-Frame Insertions]
	 Old: A278_T345ins [bZIP Region In-Frame Insertions]
CEBPA P272_R358del [bZIP Region In-Frame Deletions] Name Changed
	 New: P272_R358del [bZIP Region In-Frame Deletions]
	 Old: A278_T345del [bZIP Region In-Frame Deletions]
CEBPA P272_R358trunc [bZIP Region Truncating Mutations] Name Changed
	 New: P272_R358trunc [bZIP Region Truncating Mutations]
	 Old: A278_T345trunc [bZIP Domain Truncating Mutations]
CEBPA Oncogenic Mutations Deleted
CEBPA M1_V119trunc [N-terminal Truncating Mutations] Name Changed
	 New: M1_V119trunc [N-terminal Truncating Mutations]
	 Old: M1_V119trunc
COP1 Summary Updated
COP1 Background Updated
CTDNEP1 R158A Added
CTDNEP1 E70S Added
CTDNEP1 D67N Added
CTDNEP1 D69N Added
CTDNEP1 L72H Added
CTDNEP1 Background Updated
CTDNEP1 Summary Updated
CTDNEP1 Truncating Mutations Added
CTDNEP1 Deletion Added
CXCR4 V320Efs*23 Added
ETV6 Q347P Added
ETV6 W380R Added
ETV6 R396G Added
ETV6 R399H Added
ETV6 S22N Added
ETV6 H224Q Added
FGFR1 FN1-FGFR1 Fusion Added
FOXP1 Amplification Added
H1-4 A167V Added
IDH2 R172 Deleted
MEF2B T70R Added
MYC P72S
MYC S161L
NSD1 T2029A
NSD1 R2017L Added
NSD1 Y1971C Added
NSD2 Summary Updated
NSD2 IGH-NSD2 Fusion Added
PIK3CA Oncogenic Mutations {excluding C420R ; E542K ; E545A ; E545D ; E545G ; E545K ; Q546E ; Q546R ; H1047L ; H1047R ; H1047Y} Name Changed
	 New: Oncogenic Mutations {excluding C420R ; E542K ; E545A ; E545D ; E545G ; E545K ; Q546E ; Q546R ; H1047L ; H1047R ; H1047Y}
	 Old: Oncogenic Mutations {excluding C420R, E542K, E545A, E545D, E545G, E545K, Q546E, Q546R, H1047L, H1047R, H1047Y}
PIM1 L182F Added
PLCG1 R48W Added
POLD1 L474P Added
PPP2R1A Oncogenic Mutations Added
RIOK2 Background Updated
RRAGC T90N Added
SAMD9 Summary Updated
SAMD9 Background Updated
SAMD9L Background Updated
SAMD9L Summary Updated
SMARCA1 Background Updated
SMARCA1 Summary Updated
SMARCA1 Deletion Added
SOCS1 F79L Added
STAT6 E372K Added
STAT6 N430T Added
STAT6 D419H Added
STAT6 N417Y Added
STAT6 N421K Added
USP6 Background Updated
USP6 Summary Updated
USP6 Amplification Added
USP6 MYH9-USP6 Fusion Added
USP6 CNBP-USP6 Fusion Added
USP6 COL1A1-USP6 Fusion Added
WRN Summary Updated
WRN Background Updated
WRN Truncating Mutations Added
```

### Evidence

```
ABL1 BCR-ABL1 Fusion, Chronic Myelogenous Leukemia, Asciminib, Additional Information Updated
ABL1 T315I, Chronic Myelogenous Leukemia, Asciminib, Description Updated
ABL1 T315I, Chronic Myelogenous Leukemia, Ponatinib, Description Updated
ABL1 T315I, Chronic Myelogenous Leukemia, Ponatinib, Additional Information Updated
ABL1 BCR-ABL1 Fusion, Chronic Myeloid Leukemia, BCR-ABL1 + , Diagnostic, Relevant Cancer Types Updated
ALK I1171N, Mutation Effect, Description Updated
ALK Fusions, ALK Positive Large B-Cell Lymphoma, Diagnostic, Relevant Cancer Types Updated
AR T878S, Mutation Effect, Description Updated
AR L702H, Mutation Effect, Description Updated
AR F877L, Mutation Effect, Description Updated
AR T878A, Mutation Effect, Description Updated
ATP6V1B2 Y371C, Mutation Effect, Description Updated
ATP6V1B2 R400Q, Mutation Effect, Description Updated
BIRC3 Gene Type, Oncogene Updated
BIRC3 Gene Type, Tumor Suppressor Updated
BRCA1 Oncogenic Mutations, Pancreatic Adenocarcinoma, Acinar Cell Carcinoma of the Pancreas, Olaparib, Description Updated
BRCA1 N810Y, Mutation Effect, Description Updated
BRCA1 C61G, Mutation Effect, Description Updated
BRCA1 R71G, Mutation Effect, Description Updated
BRCA1 L246V, Mutation Effect, Description Updated
BRCA1 C64R, Mutation Effect, Description Updated
BRCA1 D67Y, Mutation Effect, Description Updated
BRCA1 D67Y, Mutation Effect, Effect Updated
BRCA1 D67Y, Mutation Effect, Oncogenic Updated
BRCA1 S316G, Mutation Effect, Description Updated
BRCA1 S316G, Mutation Effect, Effect Updated
BRCA1 S316G, Mutation Effect, Oncogenic Updated
BRCA1 Q356R, Mutation Effect, Description Updated
BRCA1 Q356R, Mutation Effect, Effect Updated
BRCA1 Q356R, Mutation Effect, Oncogenic Updated
BRCA1 C61G, Mutation Effect, Oncogenic Updated
BRCA1 E23fs (185delAG) (germline), Mutation Effect, Description Updated
BRCA1 I379M, Mutation Effect, Description Updated
BRCA1 I379M, Mutation Effect, Effect Updated
BRCA1 I379M, Mutation Effect, Oncogenic Updated
BRCA2 Oncogenic Mutations, Pancreatic Adenocarcinoma, Acinar Cell Carcinoma of the Pancreas, Olaparib, Description Updated
BRCA2 S2695L, Mutation Effect, Description Updated
BTG1 Q36H, Mutation Effect, Description Updated
BTG1 Q36H, Mutation Effect, Effect Updated
BTG1 Q36H, Mutation Effect, Oncogenic Updated
CCNE1 Amplification, All Solid Tumors, Summary Updated
CCNE1 Amplification, All Solid Tumors, BLU-222 Added
CCNE1 Amplification, All Solid Tumors, Lunresertib, BLU-222, Description Updated
CCNE1 Amplification, All Solid Tumors, Lunresertib + Camonsertib, Description Updated
CCNE1 Amplification, All Solid Tumors, Lunresertib + Camonsertib, FDA Level Updated
CCNE1 Amplification, All Solid Tumors, Lunresertib + Camonsertib, Level Updated
CCNE1 Amplification, All Solid Tumors, Lunresertib + Camonsertib, Propagation to Other Liquid Tumor Types Updated
CCNE1 Amplification, All Solid Tumors, Lunresertib + Camonsertib, Propagation to Other Solid Tumor Types Updated
CCNE1 Amplification, All Solid Tumors, Lunresertib + Camonsertib Added
CCNE1 Amplification, Endometrial Cancer, Ovarian Cancer, Summary Updated
CCNE1 Amplification, Endometrial Cancer, Ovarian Cancer, Lunresertib + Camonsertib, Description Updated
CCNE1 Amplification, Endometrial Cancer, Ovarian Cancer, Lunresertib + Camonsertib, FDA Level Updated
CCNE1 Amplification, Endometrial Cancer, Ovarian Cancer, Lunresertib + Camonsertib, Level Updated
CCNE1 Amplification, Endometrial Cancer, Ovarian Cancer, Lunresertib + Camonsertib, Propagation to Other Liquid Tumor Types Updated
CCNE1 Amplification, Endometrial Cancer, Ovarian Cancer, Lunresertib + Camonsertib, Propagation to Other Solid Tumor Types Updated
CCNE1 Amplification, Endometrial Cancer, Ovarian Cancer Added
CCNE1 Amplification, Endometrial Cancer, Ovarian Cancer, Lunresertib + Camonsertib Added
CCNE1 Amplification, All Solid Tumors, BLU-222 Deleted
CCNE1 Amplification, All Solid Tumors, Lunresertib Name Changed
	 New: a8ec1f1e-8de5-4dbc-a640-4c81218fe910
	 Old: a8ec1f1e-8de5-4dbc-a640-4c81218fe910, a01d8b42-2073-484a-8020-45f2920f7cab
CCNE1 Amplification, All Solid Tumors, Lunresertib, Description Updated
CCNE1 Amplification, All Solid Tumors, BLU-222, Description Updated
CCNE1 Amplification, All Solid Tumors, BLU-222, FDA Level Updated
CCNE1 Amplification, All Solid Tumors, BLU-222, Level Updated
CCNE1 Amplification, All Solid Tumors, BLU-222, Propagation to Other Liquid Tumor Types Updated
CCNE1 Amplification, All Solid Tumors, BLU-222, Propagation to Other Solid Tumor Types Updated
CDKN2A P72L, Mutation Effect, Description Updated
CDKN2A P72L, Mutation Effect, Effect Updated
CDKN2A P72L, Mutation Effect, Oncogenic Updated
CDKN2A G65R, Mutation Effect, Description Updated
CDKN2A G65R, Mutation Effect, Effect Updated
CDKN2A G65R, Mutation Effect, Oncogenic Updated
CDKN2A G65S, Mutation Effect, Description Updated
CDKN2A G65S, Mutation Effect, Effect Updated
CDKN2A G65S, Mutation Effect, Oncogenic Updated
CDKN2A D68H, Mutation Effect, Description Updated
CDKN2A D68H, Mutation Effect, Effect Updated
CDKN2A D68H, Mutation Effect, Oncogenic Updated
CEBPA P282_S334ins [bZIP Domain In-Frame Insertions], Mutation Effect, Description Updated
CEBPA P282_S334ins [bZIP Domain In-Frame Insertions], Mutation Effect, Effect Updated
CEBPA P282_S334ins [bZIP Domain In-Frame Insertions], Mutation Effect, Oncogenic Updated
CEBPA P282_S334del [bZIP Domain In-Frame Deletions], Mutation Effect, Description Updated
CEBPA P282_S334del [bZIP Domain In-Frame Deletions], Mutation Effect, Effect Updated
CEBPA P282_S334del [bZIP Domain In-Frame Deletions], Mutation Effect, Oncogenic Updated
CEBPA P282_S334trunc [bZIP Domain Truncating Mutations], Mutation Effect, Description Updated
CEBPA P282_S334trunc [bZIP Domain Truncating Mutations], Mutation Effect, Effect Updated
CEBPA P282_S334trunc [bZIP Domain Truncating Mutations], Mutation Effect, Oncogenic Updated
CEBPA Truncating Mutations, Mutation Effect, Description Updated
CEBPA A278_T345ins [bZIP Region In-Frame Insertions], Mutation Effect, Description Updated
CEBPA A278_T345del [bZIP Region In-Frame Deletions], Mutation Effect, Description Updated
CEBPA A278_T345ins, A278_T345del, AML with Biallelic Mutations of CEBPA, Diagnostic Summary Updated
CEBPA A278_T345ins, A278_T345del, AML with Biallelic Mutations of CEBPA, Prognostic Summary Updated
CEBPA A278_T345ins, A278_T345del, AML with Biallelic Mutations of CEBPA, Prognostic, Description Updated
CEBPA A278_T345ins, A278_T345del, AML with Biallelic Mutations of CEBPA, Prognostic, Level Updated
CEBPA A278_T345ins, A278_T345del, AML with Biallelic Mutations of CEBPA Added
CEBPA A278_T345ins, A278_T345del, Acute Myeloid Leukemia, Diagnostic Summary Updated
CEBPA A278_T345ins, A278_T345del, Acute Myeloid Leukemia, Prognostic Summary Updated
CEBPA A278_T345ins, A278_T345del, Acute Myeloid Leukemia, Prognostic, Description Updated
CEBPA A278_T345ins, A278_T345del, Acute Myeloid Leukemia, Prognostic, Level Updated
CEBPA A278_T345ins, A278_T345del Added
CEBPA A278_T345ins, A278_T345del, Acute Myeloid Leukemia Added
CEBPA M1_V119trunc, Acute Myeloid Leukemia, Diagnostic Summary Updated
CEBPA M1_V119trunc, Acute Myeloid Leukemia Added
CEBPA Oncogenic Mutations, AML with Biallelic Mutations of CEBPA, Diagnostic Summary Updated
CEBPA Oncogenic Mutations, Acute Myeloid Leukemia Deleted
CEBPA A278_T345trunc [bZIP Domain Truncating Mutations], Mutation Effect, Description Updated
CEBPA M1_V119trunc, Mutation Effect, Description Updated
CEBPA M1_V119trunc, Mutation Effect, Effect Updated
CEBPA M1_V119trunc, Mutation Effect, Oncogenic Updated
CEBPA K313dup, Mutation Effect, Description Updated
CEBPA K313dup, Mutation Effect, Effect Updated
CEBPA K313dup, Mutation Effect, Oncogenic Updated
CEBPA R297G, Mutation Effect, Description Updated
CEBPA R297G, Mutation Effect, Effect Updated
CEBPA R297G, Mutation Effect, Oncogenic Updated
CEBPA K298T, Mutation Effect, Description Updated
CEBPA K298T, Mutation Effect, Effect Updated
CEBPA K298T, Mutation Effect, Oncogenic Updated
CEBPA R300G, Mutation Effect, Description Updated
CEBPA R300G, Mutation Effect, Effect Updated
CEBPA R300G, Mutation Effect, Oncogenic Updated
CEBPA K302N, Mutation Effect, Description Updated
CEBPA K302N, Mutation Effect, Effect Updated
CEBPA K302N, Mutation Effect, Oncogenic Updated
CEBPA Oncogenic Mutations, AML with Biallelic Mutations of CEBPA Deleted
CEBPA P272_R358ins [bZIP Region In-Frame Insertions], Mutation Effect, Description Updated
CEBPA P272_R358del [bZIP Region In-Frame Deletions], Mutation Effect, Description Updated
CEBPA P272_R358trunc [bZIP Region Truncating Mutations], Mutation Effect, Description Updated
CEBPA P272_R358ins [bZIP Region In-Frame Insertions], P272_R358del [bZIP Region In-Frame Deletions], R300G Name Changed
	 New: P272_R358ins [bZIP Region In-Frame Insertions], P272_R358del [bZIP Region In-Frame Deletions], R300G
	 Old: A278_T345ins, A278_T345del
CEBPA P272_R358trunc [bZIP Region Truncating Mutations], Acute Myeloid Leukemia, Diagnostic Summary Updated
CEBPA P272_R358trunc [bZIP Region Truncating Mutations], Acute Myeloid Leukemia Added
CEBPA P272_R358ins [bZIP Region In-Frame Insertions], P272_R358del [bZIP Region In-Frame Deletions], R300G, AML with Biallelic Mutations of CEBPA, Diagnostic, Description Updated
CEBPA P272_R358ins [bZIP Region In-Frame Insertions], P272_R358del [bZIP Region In-Frame Deletions], R300G, AML with Biallelic Mutations of CEBPA, Diagnostic, Level Updated
CEBPA P272_R358ins [bZIP Region In-Frame Insertions], P272_R358del [bZIP Region In-Frame Deletions], R300G, Acute Myeloid Leukemia, Diagnostic Summary Updated
CEBPA P272_R358ins [bZIP Region In-Frame Insertions], P272_R358del [bZIP Region In-Frame Deletions], R300G, Acute Myeloid Leukemia, Diagnostic, Description Updated
CEBPA M1_V119trunc [N-terminal Truncating Mutations], Acute Myeloid Leukemia, Diagnostic Summary Updated
CEBPA P272_R358ins [bZIP Region In-Frame Insertions], P272_R358del [bZIP Region In-Frame Deletions], R300G, AML with Biallelic Mutations of CEBPA, Diagnostic Summary Updated
COP1 Deletion, Mutation Effect, Description Updated
COP1 Gene Type, Tumor Suppressor Updated
CTDNEP1 Gene Type, Tumor Suppressor Updated
CTDNEP1 R158A, Mutation Effect, Description Updated
CTDNEP1 R158A, Mutation Effect, Effect Updated
CTDNEP1 R158A, Mutation Effect, Oncogenic Updated
CTDNEP1 E70S, Mutation Effect, Description Updated
CTDNEP1 E70S, Mutation Effect, Effect Updated
CTDNEP1 E70S, Mutation Effect, Oncogenic Updated
CTDNEP1 D67N, Mutation Effect, Description Updated
CTDNEP1 D67N, Mutation Effect, Effect Updated
CTDNEP1 D67N, Mutation Effect, Oncogenic Updated
CTDNEP1 D69N, Mutation Effect, Description Updated
CTDNEP1 D69N, Mutation Effect, Effect Updated
CTDNEP1 D69N, Mutation Effect, Oncogenic Updated
CTDNEP1 L72H, Mutation Effect, Description Updated
CTDNEP1 L72H, Mutation Effect, Effect Updated
CTDNEP1 L72H, Mutation Effect, Oncogenic Updated
CTDNEP1 Truncating Mutations, Mutation Effect, Description Updated
CTDNEP1 Truncating Mutations, Mutation Effect, Effect Updated
CTDNEP1 Truncating Mutations, Mutation Effect, Oncogenic Updated
CTDNEP1 Deletion, Mutation Effect, Description Updated
CTDNEP1 Deletion, Mutation Effect, Effect Updated
CTDNEP1 Deletion, Mutation Effect, Oncogenic Updated
CXCR4 V320Efs*23, Mutation Effect, Description Updated
CXCR4 V320Efs*23, Mutation Effect, Effect Updated
CXCR4 V320Efs*23, Mutation Effect, Oncogenic Updated
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Osimertinib, Additional Information Updated
ETV6 R369W, Mutation Effect, Description Updated
ETV6 R369W, Mutation Effect, Effect Updated
ETV6 R369W, Mutation Effect, Oncogenic Updated
ETV6 Q347P, Mutation Effect, Description Updated
ETV6 Q347P, Mutation Effect, Effect Updated
ETV6 Q347P, Mutation Effect, Oncogenic Updated
ETV6 W380R, Mutation Effect, Description Updated
ETV6 W380R, Mutation Effect, Effect Updated
ETV6 W380R, Mutation Effect, Oncogenic Updated
ETV6 R396G, Mutation Effect, Description Updated
ETV6 R396G, Mutation Effect, Effect Updated
ETV6 R396G, Mutation Effect, Oncogenic Updated
ETV6 R399H, Mutation Effect, Description Updated
ETV6 R399H, Mutation Effect, Effect Updated
ETV6 R399H, Mutation Effect, Oncogenic Updated
ETV6 S22N, Mutation Effect, Description Updated
ETV6 S22N, Mutation Effect, Effect Updated
ETV6 S22N, Mutation Effect, Oncogenic Updated
ETV6 H224Q, Mutation Effect, Description Updated
ETV6 H224Q, Mutation Effect, Effect Updated
ETV6 H224Q, Mutation Effect, Oncogenic Updated
FBXW7 Oncogenic Mutations, All Solid Tumors, Summary Updated
FBXW7 Oncogenic Mutations, All Solid Tumors, Lunresertib + Camonsertib, Description Updated
FBXW7 Oncogenic Mutations, All Solid Tumors, Lunresertib + Camonsertib, FDA Level Updated
FBXW7 Oncogenic Mutations, All Solid Tumors, Lunresertib + Camonsertib, Level Updated
FBXW7 Oncogenic Mutations, All Solid Tumors, Lunresertib + Camonsertib, Propagation to Other Liquid Tumor Types Updated
FBXW7 Oncogenic Mutations, All Solid Tumors, Lunresertib + Camonsertib, Propagation to Other Solid Tumor Types Updated
FBXW7 Oncogenic Mutations, All Solid Tumors Added
FBXW7 Oncogenic Mutations, All Solid Tumors, Lunresertib + Camonsertib Added
FBXW7 Oncogenic Mutations, Endometrial Cancer, Ovarian Cancer, Summary Updated
FBXW7 Oncogenic Mutations, Endometrial Cancer, Ovarian Cancer, Lunresertib + Camonsertib, Description Updated
FBXW7 Oncogenic Mutations, Endometrial Cancer, Ovarian Cancer, Lunresertib + Camonsertib, FDA Level Updated
FBXW7 Oncogenic Mutations, Endometrial Cancer, Ovarian Cancer, Lunresertib + Camonsertib, Level Updated
FBXW7 Oncogenic Mutations, Endometrial Cancer, Ovarian Cancer, Lunresertib + Camonsertib, Propagation to Other Liquid Tumor Types Updated
FBXW7 Oncogenic Mutations, Endometrial Cancer, Ovarian Cancer, Lunresertib + Camonsertib, Propagation to Other Solid Tumor Types Updated
FBXW7 Oncogenic Mutations, Endometrial Cancer, Ovarian Cancer Added
FBXW7 Oncogenic Mutations, Endometrial Cancer, Ovarian Cancer, Lunresertib + Camonsertib Added
FGFR1 FN1-FGFR1 Fusion, Mutation Effect, Description Updated
FGFR1 FN1-FGFR1 Fusion, Mutation Effect, Effect Updated
FGFR1 FN1-FGFR1 Fusion, Mutation Effect, Oncogenic Updated
FLT3 572_630ins [Internal tandem duplication], Acute Myeloid Leukemia, Crenolanib, Description Updated
FOXP1 Truncating Mutations, Mutation Effect, Description Updated
FOXP1 Amplification, Mutation Effect, Description Updated
FOXP1 Amplification, Mutation Effect, Effect Updated
FOXP1 Amplification, Mutation Effect, Oncogenic Updated
H1-4 A167V, Mutation Effect, Description Updated
H1-4 A167V, Mutation Effect, Effect Updated
H1-4 A167V, Mutation Effect, Oncogenic Updated
IDH1 R132, Oligodendroglioma, Astrocytoma, Vorasidenib, Description Updated
IDH1 R132, Oligodendroglioma, Astrocytoma, Vorasidenib, FDA Level Updated
IDH1 R132, Oligodendroglioma, Astrocytoma, Vorasidenib, Level Updated
IDH1 R132, Oligodendroglioma, Astrocytoma, Vorasidenib, Propagation to Other Liquid Tumor Types Updated
IDH1 R132, Astrocytoma Deleted
IDH1 R132, Oligodendroglioma, Astrocytoma, Summary Updated
IDH1 Oncogenic Mutations, Oligodendroglioma, Astrocytoma Name Changed
	 New: Oligodendroglioma, Astrocytoma
	 Old: Oligodendroglioma
IDH1 Oncogenic Mutations, Oligodendroglioma, Astrocytoma, Summary Updated
IDH1 Oncogenic Mutations, Oligodendroglioma, Astrocytoma, Ivosidenib, Description Updated
IDH1 R132, Oligodendroglioma, Astrocytoma Deleted
IDH1 Oncogenic Mutations, Oligodendroglioma, Astrocytoma, Vorasidenib, Description Updated
IDH1 Oncogenic Mutations, Oligodendroglioma, Astrocytoma, Vorasidenib, FDA Level Updated
IDH1 Oncogenic Mutations, Oligodendroglioma, Astrocytoma, Vorasidenib, Level Updated
IDH1 Oncogenic Mutations, Oligodendroglioma, Astrocytoma, Vorasidenib, Propagation to Other Liquid Tumor Types Updated
IDH1 Oncogenic Mutations, Oligodendroglioma, Astrocytoma, Vorasidenib, Propagation to Other Solid Tumor Types Updated
IDH1 R132, Glioma {excluding Oligodendroglioma, Astrocytoma} Name Changed
	 New: Glioma {excluding Oligodendroglioma, Astrocytoma}
	 Old: Glioma {excluding Oligodendroglioma}
IDH1 R132, Glioma Name Changed
	 New: Glioma
	 Old: Glioma {excluding Oligodendroglioma, Astrocytoma}
IDH1 R132C, R132H, R132G, R132S, R132L, Astrocytoma, Oligodendroglioma, Summary Updated
IDH1 R132C, R132H, R132G, R132S, R132L, Astrocytoma, Oligodendroglioma, Vorasidenib, Description Updated
IDH1 R132C, R132H, R132G, R132S, R132L, Astrocytoma, Oligodendroglioma, Vorasidenib, FDA Level Updated
IDH1 R132C, R132H, R132G, R132S, R132L, Astrocytoma, Oligodendroglioma, Vorasidenib, Level Updated
IDH1 R132C, R132H, R132G, R132S, R132L, Astrocytoma, Oligodendroglioma, Vorasidenib, Propagation to Other Liquid Tumor Types Updated
IDH1 R132C, R132H, R132G, R132S, R132L, Astrocytoma, Oligodendroglioma, Vorasidenib, Propagation to Other Solid Tumor Types Updated
IDH1 R132C, R132H, R132G, R132S, R132L, Astrocytoma, Oligodendroglioma Added
IDH1 R132C, R132H, R132G, R132S, R132L, Astrocytoma, Oligodendroglioma, Vorasidenib Added
IDH1 R132C, R132H, R132G, R132S, R132L, Myelodysplastic Syndromes, Summary Updated
IDH1 Oncogenic Mutations, Other Tumor Types, Summary Updated
IDH1 R132C, R132H, R132G, R132S, R132L, Acute Myeloid Leukemia, Ivosidenib, Propagation to Other Liquid Tumor Types Updated
IDH1 R132C, R132H, R132G, R132S, R132L, Acute Myeloid Leukemia, Ivosidenib, Propagation to Other Solid Tumor Types Updated
IDH1 R132C, R132H, R132G, R132S, R132L, Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma Added
IDH1 R132, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma Deleted
IDH2 R172, Oligodendroglioma, Astrocytoma, Summary Updated
IDH2 R172, Oligodendroglioma, Astrocytoma, Vorasidenib, Description Updated
IDH2 R172, Oligodendroglioma, Astrocytoma, Vorasidenib, FDA Level Updated
IDH2 R172, Oligodendroglioma, Astrocytoma, Vorasidenib, Level Updated
IDH2 R172, Oligodendroglioma, Astrocytoma, Vorasidenib, Propagation to Other Liquid Tumor Types Updated
IDH2 Oncogenic Mutations, Oligodendroglioma, Astrocytoma, Summary Updated
IDH2 Oncogenic Mutations, Oligodendroglioma, Astrocytoma, Vorasidenib, Description Updated
IDH2 Oncogenic Mutations, Oligodendroglioma, Astrocytoma, Vorasidenib, FDA Level Updated
IDH2 Oncogenic Mutations, Oligodendroglioma, Astrocytoma, Vorasidenib, Level Updated
IDH2 Oncogenic Mutations, Oligodendroglioma, Astrocytoma, Vorasidenib, Propagation to Other Liquid Tumor Types Updated
IDH2 Oncogenic Mutations, Oligodendroglioma, Astrocytoma, Vorasidenib, Propagation to Other Solid Tumor Types Updated
IDH2 Oncogenic Mutations, Oligodendroglioma, Astrocytoma Added
IDH2 Oncogenic Mutations, Oligodendroglioma, Astrocytoma, Vorasidenib Added
IDH2 R172, Oligodendroglioma, Astrocytoma Deleted
IDH2 R172K, R172M, R172W, R172S, R172G, Astrocytoma, Oligodendroglioma, Summary Updated
IDH2 R172K, R172M, R172W, R172S, R172G, Astrocytoma, Oligodendroglioma, Vorasidenib, Description Updated
IDH2 R172K, R172M, R172W, R172S, R172G, Astrocytoma, Oligodendroglioma, Vorasidenib, FDA Level Updated
IDH2 R172K, R172M, R172W, R172S, R172G, Astrocytoma, Oligodendroglioma, Vorasidenib, Level Updated
IDH2 R172K, R172M, R172W, R172S, R172G, Astrocytoma, Oligodendroglioma, Vorasidenib, Propagation to Other Liquid Tumor Types Updated
IDH2 R172K, R172M, R172W, R172S, R172G, Astrocytoma, Oligodendroglioma, Vorasidenib, Propagation to Other Solid Tumor Types Updated
IDH2 R172K, R172M, R172W, R172S, R172G Added
IDH2 R172K, R172M, R172W, R172S, R172G, Astrocytoma, Oligodendroglioma Added
IDH2 R172K, R172M, R172W, R172S, R172G, Astrocytoma, Oligodendroglioma, Vorasidenib Added
IDH2 Oncogenic Mutations, Oligodendroglioma, Astrocytoma Deleted
IDH2 Oncogenic Mutations, Other Tumor Types, Summary Updated
IDH2 R140Q, R140L, R140G, R140W, R172K, R172M, R172G, R172S, R172W, Acute Myeloid Leukemia, Enasidenib, Propagation to Other Liquid Tumor Types Updated
IDH2 R140Q, R140L, R140G, R140W, R172K, R172M, R172G, R172S, R172W, Acute Myeloid Leukemia, Enasidenib, Propagation to Other Solid Tumor Types Updated
IRF4 Fusions, Large B-Cell Lymphoma with IRF4 Rearrangement, Diagnostic, Relevant Cancer Types Updated
JAK1 G1097D, Mutation Effect, Description Updated
KRAS G12A, D, R, S, V, Pancreatic Adenocarcinoma, RMC-6236, Description Updated
KRAS G12A, D, R, S, V, Non-Small Cell Lung Cancer, RMC-6236, Description Updated
KRAS G12A, D, R, S, V, All Solid Tumors Name Changed
	 New: All Solid Tumors
	 Old: All Solid Tumors {excluding Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer}
KRAS G12C, Non-Small Cell Lung Cancer, Adagrasib, Additional Information Updated
KRAS G12C, Non-Small Cell Lung Cancer, Adagrasib, Description Updated
KRAS G12A, D, R, S, V, Pancreatic Adenocarcinoma, RMC-6236, Propagation to Other Solid Tumor Types Updated
KRAS G12A, D, R, S, V, Non-Small Cell Lung Cancer, RMC-6236, Propagation to Other Solid Tumor Types Updated
MDM2 Amplification, Well-Differentiated Liposarcoma, Brigimadlin, Propagation to Other Solid Tumor Types Updated
MDM2 Amplification, Dedifferentiated Liposarcoma, Brigimadlin, Propagation to Other Solid Tumor Types Updated
MDM2 Amplification, Biliary Tract Cancer, NOS, Brigimadlin, Brigimadlin + Ezabenlimab, Propagation to Other Solid Tumor Types Updated
MEF2B T70R, Mutation Effect, Description Updated
MEF2B T70R, Mutation Effect, Effect Updated
MEF2B T70R, Mutation Effect, Oncogenic Updated
MET D1010, Mutation Effect, Description Updated
MET E168D, Mutation Effect, Description Updated
MET E168D, Mutation Effect, Effect Updated
MET E168D, Mutation Effect, Oncogenic Updated
MTOR L2427Q, L2209V, Renal Cell Carcinoma, Temsirolimus, Propagation to Other Solid Tumor Types Updated
MYC P72S, Mutation Effect, Description Updated
MYC P72S, Mutation Effect, Effect Updated
MYC P72S, Mutation Effect, Oncogenic Updated
MYC S161L, Mutation Effect, Description Updated
MYC S161L, Mutation Effect, Effect Updated
MYC S161L, Mutation Effect, Oncogenic Updated
MYC Fusions, High-Grade B-Cell Lymphoma, with MYC and BCL2 and, or BCL6 Rearrangements, Diagnostic, Relevant Cancer Types Updated
NSD1 T2029A, Mutation Effect, Description Updated
NSD1 T2029A, Mutation Effect, Effect Updated
NSD1 T2029A, Mutation Effect, Oncogenic Updated
NSD1 R2017L, Mutation Effect, Description Updated
NSD1 R2017L, Mutation Effect, Effect Updated
NSD1 R2017L, Mutation Effect, Oncogenic Updated
NSD1 Y1971C, Mutation Effect, Description Updated
NSD1 Y1971C, Mutation Effect, Effect Updated
NSD1 Y1971C, Mutation Effect, Oncogenic Updated
NSD2 IGH-NSD2, Plasma Cell Myeloma, Prognostic Summary Updated
NSD2 IGH-NSD2 Fusion, Mutation Effect, Description Updated
NSD2 IGH-NSD2 Fusion, Mutation Effect, Effect Updated
NSD2 IGH-NSD2 Fusion, Mutation Effect, Oncogenic Updated
NSD2 IGH-NSD2 Fusion, Plasma Cell Myeloma, Prognostic, Description Updated
NSD2 IGH-NSD2 Fusion, Plasma Cell Myeloma, Prognostic, Level Updated
NSD2 IGH-NSD2 Fusion, Plasma Cell Myeloma Added
PIK3CA H1047R, Mutation Effect, Description Updated
PIK3CA Oncogenic Mutations, Breast Cancer, Inavolisib + Palbociclib + Fulvestrant, Description Updated
PIK3CA Oncogenic Mutations, Breast Cancer, Inavolisib + Palbociclib + Fulvestrant, Propagation to Other Liquid Tumor Types Updated
PIK3CA Oncogenic Mutations, Breast Cancer, Inavolisib + Palbociclib + Fulvestrant, Level Updated
PIK3CA Oncogenic Mutations, Breast Cancer, Inavolisib + Palbociclib + Fulvestrant, FDA Level Updated
PIK3CA Oncogenic Mutations, Breast Cancer, Inavolisib + Palbociclib + Fulvestrant Added
PIK3CA Oncogenic Mutations, Breast Cancer, Inavolisib + Palbociclib + Fulvestrant, Propagation to Other Solid Tumor Types Updated
PIK3CA Oncogenic Mutations, Other Tumor Types, Summary Updated
PIK3CA Oncogenic Mutations, Other Tumor Types Deleted
PIK3CA Oncogenic Mutations {excluding C420R; E542K; E545A; E545D; E545G; E545K; Q546E; Q546R; H1047L; H1047R; H1047Y; R88Q; N345K; E545Q; Q546K; Q546P; M1043V; M1043I; G1049R}, Breast Cancer, Alpelisib + Fulvestrant Deleted
PIK3CA Oncogenic Mutations {excluding C420R, E542K, E545A, E545D, E545G, E545K, Q546E, Q546R, H1047L, H1047R, H1047Y} Added
PIK3CA Oncogenic Mutations {excluding C420R ; E542K ; E545A ; E545D ; E545G ; E545K ; Q546E ; Q546R ; H1047L ; H1047R ; H1047Y}, Breast Cancer Name Changed
	 New: Breast Cancer
	 Old: Breast
PIK3CA R88Q, N345K, E545Q, Q546K, Q546P, M1043V, M1043I, G1049R, Other Solid Tumor Types Added
PIK3CA Oncogenic Mutations {excluding C420R ; E542K ; E545A ; E545D ; E545G ; E545K ; Q546E ; Q546R ; H1047L ; H1047R ; H1047Y}, Other Solid Tumor Types Added
PIK3CA C420R, E542K, E545A, E545D, E545G, E545K, Q546E, Q546R, H1047L, H1047R, H1047Y, Other Liquid Tumor Types Name Changed
	 New: Other Liquid Tumor Types
	 Old: Other Tumor Types
PIK3CA R88Q, N345K, E545Q, Q546K, Q546P, M1043V, M1043I, G1049R, Other Liquid Tumor Types Name Changed
	 Old: Other Solid Tumor Types
PIK3CA Oncogenic Mutations {excluding C420R; E542K; E545A; E545D; E545G; E545K; Q546E; Q546R; H1047L; H1047R; H1047Y; R88Q; N345K; E545Q; Q546K; Q546P; M1043V; M1043I; G1049R}, Other Liquid Tumor Types Name Changed
PIK3CA Oncogenic Mutations {excluding C420R ; E542K ; E545A ; E545D ; E545G ; E545K ; Q546E ; Q546R ; H1047L ; H1047R ; H1047Y}, Other Liquid Tumor Types Name Changed
PIM1 L182F, Mutation Effect, Description Updated
PIM1 L182F, Mutation Effect, Effect Updated
PIM1 L182F, Mutation Effect, Oncogenic Updated
PLCG1 R48W, Mutation Effect, Description Updated
PLCG1 R48W, Mutation Effect, Effect Updated
PLCG1 R48W, Mutation Effect, Oncogenic Updated
POLD1 L474P, Mutation Effect, Description Updated
POLD1 L474P, Mutation Effect, Effect Updated
POLD1 L474P, Mutation Effect, Oncogenic Updated
POLD1 E318K, S478N, L474P, D402N (Oncogenic Exonuclease Domain Missense Mutations) Name Changed
	 New: E318K, S478N, L474P, D402N (Oncogenic Exonuclease Domain Missense Mutations)
	 Old: E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations)
PPP2R1A Oncogenic Mutations, All Solid Tumors, Summary Updated
PPP2R1A Oncogenic Mutations, All Solid Tumors, Lunresertib + Camonsertib, Description Updated
PPP2R1A Oncogenic Mutations, All Solid Tumors, Lunresertib + Camonsertib, FDA Level Updated
PPP2R1A Oncogenic Mutations, All Solid Tumors, Lunresertib + Camonsertib, Level Updated
PPP2R1A Oncogenic Mutations, All Solid Tumors, Lunresertib + Camonsertib, Propagation to Other Liquid Tumor Types Updated
PPP2R1A Oncogenic Mutations, All Solid Tumors, Lunresertib + Camonsertib, Propagation to Other Solid Tumor Types Updated
PPP2R1A Oncogenic Mutations, All Solid Tumors Added
PPP2R1A Oncogenic Mutations, All Solid Tumors, Lunresertib + Camonsertib Added
PPP2R1A Oncogenic Mutations, Endometrial Cancer, Ovarian Cancer, Summary Updated
PPP2R1A Oncogenic Mutations, Endometrial Cancer, Ovarian Cancer, Lunresertib + Camonsertib, Description Updated
PPP2R1A Oncogenic Mutations, Endometrial Cancer, Ovarian Cancer, Lunresertib + Camonsertib, FDA Level Updated
PPP2R1A Oncogenic Mutations, Endometrial Cancer, Ovarian Cancer, Lunresertib + Camonsertib, Level Updated
PPP2R1A Oncogenic Mutations, Endometrial Cancer, Ovarian Cancer, Lunresertib + Camonsertib, Propagation to Other Liquid Tumor Types Updated
PPP2R1A Oncogenic Mutations, Endometrial Cancer, Ovarian Cancer, Lunresertib + Camonsertib, Propagation to Other Solid Tumor Types Updated
PPP2R1A Oncogenic Mutations, Endometrial Cancer, Ovarian Cancer Added
PPP2R1A Oncogenic Mutations, Endometrial Cancer, Ovarian Cancer, Lunresertib + Camonsertib Added
RET R886W, Mutation Effect, Description Updated
RRAGC T90N, Mutation Effect, Description Updated
RRAGC T90N, Mutation Effect, Effect Updated
RRAGC T90N, Mutation Effect, Oncogenic Updated
SF3B1 Oncogenic Mutations, Acute Myeloid Leukemia, Summary Updated
SF3B1 Oncogenic Mutations, Acute Myeloid Leukemia, Emavusertib, Description Updated
SF3B1 Oncogenic Mutations, Acute Myeloid Leukemia, Emavusertib, FDA Level Updated
SF3B1 Oncogenic Mutations, Acute Myeloid Leukemia, Emavusertib, Level Updated
SF3B1 Oncogenic Mutations, Acute Myeloid Leukemia, Emavusertib, Propagation to Other Liquid Tumor Types Updated
SF3B1 Oncogenic Mutations, Acute Myeloid Leukemia, Emavusertib, Propagation to Other Solid Tumor Types Updated
SF3B1 Oncogenic Mutations, Acute Myeloid Leukemia, Emavusertib Added
SF3B1 Oncogenic Mutations, Acute Myeloid Leukemia, H3B-8800 Deleted
SF3B1 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Summary Updated
SF3B1 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Ceralasertib, Description Updated
SF3B1 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Ceralasertib, FDA Level Updated
SF3B1 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Ceralasertib, Level Updated
SF3B1 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Ceralasertib, Propagation to Other Liquid Tumor Types Updated
SF3B1 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Ceralasertib, Propagation to Other Solid Tumor Types Updated
SF3B1 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Ceralasertib Added
SF3B1 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, H3B-8800 Deleted
SF3B1 Oncogenic Mutations, Myelodysplastic Syndromes, Summary Updated
SF3B1 Oncogenic Mutations, Myelodysplastic Syndromes, Emavusertib, Description Updated
SF3B1 Oncogenic Mutations, Myelodysplastic Syndromes, Emavusertib, FDA Level Updated
SF3B1 Oncogenic Mutations, Myelodysplastic Syndromes, Emavusertib, Level Updated
SF3B1 Oncogenic Mutations, Myelodysplastic Syndromes, Emavusertib, Propagation to Other Liquid Tumor Types Updated
SF3B1 Oncogenic Mutations, Myelodysplastic Syndromes, Emavusertib, Propagation to Other Solid Tumor Types Updated
SF3B1 Oncogenic Mutations, Myelodysplastic Syndromes, Emavusertib Added
SF3B1 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib, Description Updated
SF3B1 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib, FDA Level Updated
SF3B1 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib, Level Updated
SF3B1 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib, Propagation to Other Liquid Tumor Types Updated
SF3B1 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib, Propagation to Other Solid Tumor Types Updated
SF3B1 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib Added
SF3B1 Oncogenic Mutations, Myelodysplastic Syndromes, H3B-8800 Deleted
SF3B1 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes Name Changed
	 New: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
	 Old: Chronic Myelomonocytic Leukemia
SF3B1 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Summary Updated
SF3B1 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Ceralasertib, Description Updated
SF3B1 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib Deleted
SF3B1 Oncogenic Mutations, Chronic Myelomonocytic Leukemia Added
SMARCA1 Gene Type, Oncogene Updated
SMARCA1 Gene Type, Tumor Suppressor Updated
SMARCA1 Deletion, Mutation Effect, Description Updated
SMARCA1 Deletion, Mutation Effect, Effect Updated
SMARCA1 Deletion, Mutation Effect, Oncogenic Updated
SOCS1 F79L, Mutation Effect, Description Updated
SOCS1 F79L, Mutation Effect, Effect Updated
SOCS1 F79L, Mutation Effect, Oncogenic Updated
SRSF2 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Summary Updated
SRSF2 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Ceralasertib, Description Updated
SRSF2 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Ceralasertib, FDA Level Updated
SRSF2 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Ceralasertib, Level Updated
SRSF2 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Ceralasertib, Propagation to Other Liquid Tumor Types Updated
SRSF2 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Ceralasertib, Propagation to Other Solid Tumor Types Updated
SRSF2 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Ceralasertib Added
SRSF2 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, H3B-8800 Deleted
SRSF2 Oncogenic Mutations, Myelodysplastic Syndromes, Summary Updated
SRSF2 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib, Description Updated
SRSF2 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib, FDA Level Updated
SRSF2 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib, Level Updated
SRSF2 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib, Propagation to Other Liquid Tumor Types Updated
SRSF2 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib, Propagation to Other Solid Tumor Types Updated
SRSF2 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib Added
SRSF2 Oncogenic Mutations, Acute Myeloid Leukemia, H3B-8800 Deleted
SRSF2 Oncogenic Mutations, Myelodysplastic Syndromes, H3B-8800 Deleted
SRSF2 Oncogenic Mutations, Acute Myeloid Leukemia Deleted
SRSF2 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Ceralasertib Deleted
SRSF2 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib Deleted
SRSF2 Oncogenic Mutations, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Ceralasertib, Description Updated
SRSF2 Oncogenic Mutations, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia Added
SRSF2 Oncogenic Mutations, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Ceralasertib Added
SRSF2 Oncogenic Mutations, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Ceralasertib, FDA Level Updated
SRSF2 Oncogenic Mutations, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Ceralasertib, Level Updated
SRSF2 Oncogenic Mutations, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Ceralasertib, Propagation to Other Liquid Tumor Types Updated
SRSF2 Oncogenic Mutations, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Ceralasertib, Propagation to Other Solid Tumor Types Updated
STAT6 E372K, Mutation Effect, Description Updated
STAT6 E372K, Mutation Effect, Effect Updated
STAT6 E372K, Mutation Effect, Oncogenic Updated
STAT6 N430T, Mutation Effect, Description Updated
STAT6 N430T, Mutation Effect, Effect Updated
STAT6 N430T, Mutation Effect, Oncogenic Updated
STAT6 D419H, Mutation Effect, Description Updated
STAT6 D419H, Mutation Effect, Effect Updated
STAT6 D419H, Mutation Effect, Oncogenic Updated
STAT6 N417Y, Mutation Effect, Description Updated
STAT6 N417Y, Mutation Effect, Effect Updated
STAT6 N417Y, Mutation Effect, Oncogenic Updated
STAT6 N421K, Mutation Effect, Description Updated
STAT6 N421K, Mutation Effect, Effect Updated
STAT6 N421K, Mutation Effect, Oncogenic Updated
TP53 K291E, Mutation Effect, Description Updated
TP53 R282P, Mutation Effect, Description Updated
TP53 R282G, Mutation Effect, Description Updated
TP53 R282L, Mutation Effect, Description Updated
TP53 H214Q, Mutation Effect, Description Updated
TP53 H214Q, Mutation Effect, Effect Updated
TP53 K292I, Mutation Effect, Description Updated
TP53 K292I, Mutation Effect, Oncogenic Updated
TP53 R282W, Mutation Effect, Description Updated
TP53 R282W, Mutation Effect, Effect Updated
TP53 Y220C, All Solid Tumors, Summary Updated
TP53 Y220C, All Solid Tumors, Rezatapopt, Description Updated
U2AF1 Oncogenic Mutations, Acute Myeloid Leukemia, Summary Updated
U2AF1 Oncogenic Mutations, Acute Myeloid Leukemia, Emavusertib, Description Updated
U2AF1 Oncogenic Mutations, Acute Myeloid Leukemia, Emavusertib, FDA Level Updated
U2AF1 Oncogenic Mutations, Acute Myeloid Leukemia, Emavusertib, Level Updated
U2AF1 Oncogenic Mutations, Acute Myeloid Leukemia, Emavusertib, Propagation to Other Liquid Tumor Types Updated
U2AF1 Oncogenic Mutations, Acute Myeloid Leukemia, Emavusertib, Propagation to Other Solid Tumor Types Updated
U2AF1 Oncogenic Mutations, Acute Myeloid Leukemia, Emavusertib Added
U2AF1 Oncogenic Mutations, Acute Myeloid Leukemia, H3B-8800 Deleted
U2AF1 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Summary Updated
U2AF1 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Ceralasertib, Description Updated
U2AF1 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Ceralasertib, FDA Level Updated
U2AF1 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Ceralasertib, Level Updated
U2AF1 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Ceralasertib, Propagation to Other Liquid Tumor Types Updated
U2AF1 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Ceralasertib, Propagation to Other Solid Tumor Types Updated
U2AF1 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Ceralasertib Added
U2AF1 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, H3B-8800 Deleted
U2AF1 Oncogenic Mutations, Myelodysplastic Syndromes, Emavusertib, Description Updated
U2AF1 Oncogenic Mutations, Myelodysplastic Syndromes, Emavusertib, FDA Level Updated
U2AF1 Oncogenic Mutations, Myelodysplastic Syndromes, Emavusertib, Level Updated
U2AF1 Oncogenic Mutations, Myelodysplastic Syndromes, Emavusertib, Propagation to Other Liquid Tumor Types Updated
U2AF1 Oncogenic Mutations, Myelodysplastic Syndromes, Emavusertib, Propagation to Other Solid Tumor Types Updated
U2AF1 Oncogenic Mutations, Myelodysplastic Syndromes, Emavusertib Added
U2AF1 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib, Description Updated
U2AF1 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib, FDA Level Updated
U2AF1 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib, Level Updated
U2AF1 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib, Propagation to Other Liquid Tumor Types Updated
U2AF1 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib, Propagation to Other Solid Tumor Types Updated
U2AF1 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib Added
U2AF1 Oncogenic Mutations, Myelodysplastic Syndromes, H3B-8800 Deleted
U2AF1 Oncogenic Mutations, Myelodysplastic Syndromes, Summary Updated
U2AF1 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes Name Changed
U2AF1 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Summary Updated
U2AF1 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Ceralasertib, Description Updated
U2AF1 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib Deleted
U2AF1 Oncogenic Mutations, Chronic Myelomonocytic Leukemia Added
USP6 Gene Type, Oncogene Updated
USP6 Amplification, Mutation Effect, Description Updated
USP6 Amplification, Mutation Effect, Effect Updated
USP6 Amplification, Mutation Effect, Oncogenic Updated
USP6 MYH9-USP6 Fusion, Mutation Effect, Description Updated
USP6 MYH9-USP6 Fusion, Mutation Effect, Effect Updated
USP6 MYH9-USP6 Fusion, Mutation Effect, Oncogenic Updated
USP6 CNBP-USP6 Fusion, Mutation Effect, Description Updated
USP6 CNBP-USP6 Fusion, Mutation Effect, Effect Updated
USP6 CNBP-USP6 Fusion, Mutation Effect, Oncogenic Updated
USP6 COL1A1-USP6 Fusion, Mutation Effect, Description Updated
USP6 COL1A1-USP6 Fusion, Mutation Effect, Effect Updated
USP6 COL1A1-USP6 Fusion, Mutation Effect, Oncogenic Updated
WRN Gene Type, Tumor Suppressor Updated
WRN Truncating Mutations, Mutation Effect, Description Updated
WRN Truncating Mutations, Mutation Effect, Effect Updated
WRN Truncating Mutations, Mutation Effect, Oncogenic Updated
ZRSR2 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Summary Updated
ZRSR2 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Ceralasertib, Description Updated
ZRSR2 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Ceralasertib, FDA Level Updated
ZRSR2 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Ceralasertib, Level Updated
ZRSR2 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Ceralasertib, Propagation to Other Liquid Tumor Types Updated
ZRSR2 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Ceralasertib, Propagation to Other Solid Tumor Types Updated
ZRSR2 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Ceralasertib Added
ZRSR2 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, H3B-8800 Deleted
ZRSR2 Oncogenic Mutations, Myelodysplastic Syndromes, Summary Updated
ZRSR2 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib, Description Updated
ZRSR2 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib, FDA Level Updated
ZRSR2 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib, Level Updated
ZRSR2 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib, Propagation to Other Liquid Tumor Types Updated
ZRSR2 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib, Propagation to Other Solid Tumor Types Updated
ZRSR2 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib Added
ZRSR2 Oncogenic Mutations, Myelodysplastic Syndromes, H3B-8800 Deleted
ZRSR2 Oncogenic Mutations, Acute Myeloid Leukemia, H3B-8800 Deleted
ZRSR2 Oncogenic Mutations, Acute Myeloid Leukemia Deleted
ZRSR2 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes Name Changed
ZRSR2 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Summary Updated
ZRSR2 Oncogenic Mutations, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Ceralasertib, Description Updated
ZRSR2 Oncogenic Mutations, Myelodysplastic Syndromes, Ceralasertib Deleted
ZRSR2 Oncogenic Mutations, Chronic Myelomonocytic Leukemia Added
```
